ASCO 2024: What the NADINA Trial Means for Preoperative GU Cancer Studies

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial on ipilimumab with nivolumab for melanoma, and its wider implications for the genitourinary oncology field.